GCGR and diabetes mellitus: Most of the available glucagon receptor based inhibitors for the treatment of type 2 diabetes mellitus fall in the category of glucagon neutralizing antibodies [8,9] or small molecular weight glucagon receptor antagonists [10-15] which have been shown to efficiently terminate glucagon receptor action.